TherapeuticsMD Past Earnings Performance
Past criteria checks 0/6
TherapeuticsMD has been growing earnings at an average annual rate of 58.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 22.2% per year.
Key information
58.2%
Earnings growth rate
63.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -22.2% |
| Return on equity | -14.6% |
| Net Margin | -248.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
TherapeuticsMD raises $7M in private placement
Oct 03TherapeuticsMD appoints interim co-CEOs
Sep 12Therapeutics MD Q2 Earnings Preview
Aug 12TherapeuticsMD receives $15M equity investment from Rubric Capital
Aug 01TherapeuticsMD jumps 12% as top investor discloses insider purchase
Jul 19TherapeuticsMD plunges 42% as merger agreement ends
Jul 13TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition
Jul 06TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
Jun 16TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business
Mar 14TherapeuticsMD: Time For Bulls To Take A Contrarian Approach
Oct 22TherapeuticsMD: The Long Road To Profitability
Jul 08TherapeuticsMD drops 3% despite consensus beating Q1 results
May 06TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?
Feb 24
TherapeuticsMD: Annovera May Save The Day
Feb 04TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be
Jan 29What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?
Jan 27Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?
Dec 30
TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years
Dec 09TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook
Nov 25Therapeutics MD EPS beats by $0.01, beats on revenue
Nov 09Revenue & Expenses Breakdown
How TherapeuticsMD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -4 | 5 | 0 |
| 30 Jun 24 | 1 | -5 | 6 | 0 |
| 31 Mar 24 | 1 | -6 | 7 | 0 |
| 31 Dec 23 | 1 | -8 | 9 | 0 |
| 30 Sep 23 | 69 | 42 | 18 | 0 |
| 30 Jun 23 | 70 | 29 | 30 | 0 |
| 31 Mar 23 | 70 | 17 | 42 | 0 |
| 31 Dec 22 | 70 | 1 | 57 | 0 |
| 30 Sep 22 | -64 | 3 | -26 | -6 |
| 30 Jun 22 | -39 | -30 | 10 | -4 |
| 31 Mar 22 | -17 | -58 | 48 | -2 |
| 31 Dec 21 | 3 | -79 | 73 | 0 |
| 30 Sep 21 | 91 | -172 | 194 | 8 |
| 30 Jun 21 | 85 | -157 | 182 | 8 |
| 31 Mar 21 | 72 | -166 | 178 | 9 |
| 31 Dec 20 | 65 | -184 | 193 | 10 |
| 30 Sep 20 | 58 | -191 | 198 | 12 |
| 30 Jun 20 | 63 | -190 | 204 | 15 |
| 31 Mar 20 | 58 | -193 | 196 | 17 |
| 31 Dec 19 | 50 | -176 | 175 | 20 |
| 30 Sep 19 | 39 | -166 | 157 | 22 |
| 30 Jun 19 | 19 | -170 | 142 | 25 |
| 31 Mar 19 | 16 | -148 | 130 | 27 |
| 31 Dec 18 | 16 | -133 | 116 | 27 |
| 30 Sep 18 | 15 | -115 | 95 | 32 |
| 30 Jun 18 | 16 | -94 | 76 | 31 |
| 31 Mar 18 | 17 | -80 | 62 | 33 |
| 31 Dec 17 | 17 | -77 | 58 | 34 |
| 30 Sep 17 | 17 | -78 | 60 | 33 |
| 30 Jun 17 | 18 | -89 | 63 | 41 |
| 31 Mar 17 | 18 | -90 | 59 | 47 |
| 31 Dec 16 | 19 | -90 | 51 | 54 |
| 30 Sep 16 | 20 | -85 | 44 | 57 |
| 30 Jun 16 | 20 | -79 | 36 | 59 |
| 31 Mar 16 | 21 | -85 | 32 | 69 |
| 31 Dec 15 | 20 | -85 | 29 | 72 |
| 30 Sep 15 | 19 | -84 | 26 | 73 |
| 30 Jun 15 | 18 | -82 | 25 | 71 |
| 31 Mar 15 | 17 | -66 | 23 | 55 |
| 31 Dec 14 | 15 | -54 | 22 | 43 |
| 30 Sep 14 | 14 | -46 | 21 | 35 |
| 30 Jun 14 | 12 | -36 | 20 | 24 |
| 31 Mar 14 | 10 | -31 | 20 | 18 |
| 31 Dec 13 | 9 | -28 | 19 | 14 |
Quality Earnings: TXMD is currently unprofitable.
Growing Profit Margin: TXMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TXMD is unprofitable, but has reduced losses over the past 5 years at a rate of 58.2% per year.
Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: TXMD has a negative Return on Equity (-14.64%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TherapeuticsMD, Inc. is covered by 18 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Tanner | Cantor Fitzgerald & Co. |
| Robert Labick | CJS Securities, Inc. |
| Esther Rajavelu | Deutsche Bank |